Repository logo
 
Publication

Sezary Syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab

dc.contributor.authorOliveira, A.
dc.contributor.authorLobo, I.
dc.contributor.authorAlves, R.
dc.contributor.authorLima, M.
dc.contributor.authorSelores, M.
dc.date.accessioned2014-09-02T11:28:25Z
dc.date.available2014-09-02T11:28:25Z
dc.date.issued2012
dc.description.abstractCutaneous T-cell lymphomas (CTCL) comprise a group of diseases characterized by the accumulation of malignant T cells within the skin. Sezary syndrome represents an aggressive form of CTCL, in which the skin is diffusely affected and the peripheral blood is involved. It is characterized by the triad of generalized erythroderma, lymphadenopathy, and neoplastic T cells (Sezary cells) in the skin, lymph nodes, and peripheral blood. Leonine facies is rare and corresponds to the morphologic manifestation of diffuse dermal infiltration of the face. It can occur in cutaneous T-cell lymphomas that progress during years without therapy. We present the case of a 54-year-old man with Sezary syndrome presenting with leonine facies, unresponsive to conventional therapies; he exhibited a promising response to subcutaneous low-dose alemtuzumab.por
dc.identifier.citationDermatology Online Journal 17 (11): 6por
dc.identifier.issn1087-2108
dc.identifier.urihttp://hdl.handle.net/10400.16/1667
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherUniversity of Californiapor
dc.relation.publisherversionhttp://escholarship.org/uc/item/7f79243dpor
dc.titleSezary Syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumabpor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceUnited States of Americapor
oaire.citation.titleDermatology online journalpor
oaire.citation.volume17(11)por
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sezary Syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.pdf
Size:
250.76 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.35 KB
Format:
Item-specific license agreed upon to submission
Description: